Dong-A ST Faces New Wave Of Change As It Challenges Norms

Park Looks To Shake Up 'Outdated' R&D Approaches

 
• By Jung Won Shin

Dong-A ST’s president of R&D Jae-Hong Park talks to Scrip about the changes needed in the domestic pharma sector and wider industry if Korean biopharma firms are to step up to global levels.

Jae-Hong Park, President, CSO of Dong-A ST
Dong-A's R&D Focus is On Oncology, Inflammation • Source: Dong-A ST

More from South Korea

More from Focus On Asia